YIELD10 BIOSCIENCE, INC. YTEN Cash Flow

Yield10 bioscience, inc. (YTEN)
CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities
Cash flows from operating activities
Net loss
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,766	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Loss from continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-26,768	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	-31,396	-31,890	-31,973	3,630	3,544	1,729	-305	-38,785	0	0	0
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation
201	203	200	200	199	196	194	196	200	206	215	349	446	515	556	437	332	265	244	274	371	507	621	730	824	928	1,009	1,111	1,214	1,298	1,399	1,455	1,502	1,507	0	0	0
Change in fair value of warrants
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on disposal of fixed assets
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Charge for 401(k) company common stock match
116	98	84	81	80	102	108	109	108	85	90	95	149	281	291	337	341	323	333	333	342	374	373	388	386	397	414	412	426	408	390	425	449	529	0	0	0
Stock-based compensation
631	656	635	860	1,062	1,181	1,284	1,328	1,412	1,395	756	610	521	848	1,800	2,135	2,406	2,128	1,847	1,791	1,804	2,276	2,593	2,824	3,044	3,122	3,285	3,373	3,538	3,779	3,994	4,274	4,504	4,633	0	0	0
Non-cash lease expense
1,629	1,625	613	742	675	588	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred tax provision
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivables
9	-22	46	148	3	40	-110	-213	-168	-12	-63	-97	-62	-172	-78	171	98	193	48	-434	-272	-952	-273	237	-331	158	0	0	0	-	-	-	-	-	-	-	-
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0
Due from related parties
-	-	-	-	-	-	-	-	-	-1	-1	-28	-204	-145	-146	-62	110	34	47	90	94	61	9	0	0	-24	91	0	-136	-236	-328	-226	-369	71	0	0	0
Unbilled receivables
46	-46	54	60	43	1	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unbilled receivables
-	-	-	-	-	-	-	-	-	-	-245	-8	61	-29	59	-243	-505	-270	125	197	301	223	-118	-679	-686	-185	-396	297	389	68	0	0	0	-	-	-	-
Inventory
-	-	-	-	-	-	-	-	-	-	-	-	-	-180	-169	50	58	2	-280	-465	-288	-462	-52	225	-93	516	-363	-270	-269	2,288	0	0	0	-	-	-	-
Prepaid expenses and other assets
0	-9	-159	82	63	128	125	-62	-632	-660	-604	-801	-925	-1,302	-1,019	-837	783	1,081	984	935	-373	43	-428	-188	437	21	181	287	24	-108	267	33	-86	-68	0	0	0
Accounts payable
123	162	12	21	-37	41	-12	-39	-5	17	-181	-1,310	-127	-51	-152	1,212	-110	-226	13	-264	-217	-246	-54	330	413	-654	182	-511	-97	721	-288	31	185	273	0	0	0
Accrued expenses
853	502	-268	-248	-171	-1,072	-550	-1,383	-1,447	-622	-626	1,131	38	-845	-1,003	-1,562	139	62	194	45	64	-1,179	388	-13	-51	1,383	-293	296	-86	-34	-183	-576	-88	-623	0	0	0
Lease liabilities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other liabilities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from options exercised
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Lease liabilities
-	-	-	-	-	-	0	0	0	-	-900	-64	214	339	655	-150	-150	0	0	0	-12	-50	53	-125	-151	-151	0	0	0	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-23,691	-23,216	-22,729	-23,590	-23,657	-24,583	-26,535	-26,623	-30,384	-33,031	-34,575	-34,628	-31,731	0	0	0
Net cash used by discontinued operations for operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-845	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used for operating activities
-8,646	-8,654	-7,468	-7,943	-8,020	-8,754	-8,624	-8,804	-8,799	-8,202	0	0	0	-	0	0	0	-	-22,287	-22,819	-22,232	-24,536	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from investing activities
Cash flows from investing activities
Purchase of property and equipment
103	61	12	21	39	42	42	40	9	6	37	363	591	752	877	834	688	654	517	281	199	172	245	203	409	373	276	375	308	392	665	694	728	895	0	0	0
Proceeds from sale of property and equipment
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-187	-187	307	307	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of short-term investments
6,207	5,704	2,754	4,508	7,494	11,496	9,742	7,986	4,002	0	0	0	0	-	-	-	-	-	-	-	-	1,508	2,522	7,563	13,128	16,635	18,126	21,578	35,708	58,933	70,017	76,444	127,215	107,477	0	0	0
Proceeds from the sale and maturity of short-term investments
754	2,750	7,246	9,996	11,485	8,750	5,250	1,500	11	0	0	0	0	-	-	-	-	-	-	-	-	13,017	19,393	27,331	23,507	36,821	37,430	49,605	74,862	84,303	103,672	104,065	102,762	99,464	0	0	0
Net cash provided (used) by continuing operations for investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-240	6,655	11,380	16,626	19,565	9,945	19,788	19,003	27,667	38,886	25,018	33,030	26,927	-25,181	-8,908	0	0	0
Net cash provided by investing activities
-5,546	-3,015	4,480	5,467	3,952	-2,788	-4,534	-6,526	-4,000	-6	-37	10,417	10,220	9,752	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from financing activities
Proceeds from warrants exercised (Note 11)
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from warrants exercised
-	-	-	-	-	124	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from warrants exercised
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	300	300	300	309	14	14	14	13	19	0	0	0	-	-	-	-
Proceeds from registered direct offering, net of issuance costs
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent and other long-term liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-277	-154	636	18	130	-151	-481	-521	-522	-145	198	-202	-398	-508	233	770	-37,791	-37,902	-38,160	-37,619	1,333	0	0	0
Net cash provided by financing activities
12,410	14,079	2,579	2,579	2,591	118	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash, cash equivalents and restricted cash
-66	-16	-20	-19	-26	-25	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net (decrease) increase in cash, cash equivalents and restricted cash
-1,848	2,394	-429	84	-1,503	-11,449	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	25,214	25,213	300	309	14	14	14	13	19	22	21	49,382	49,407	0	0	0
Effect of exchange rate changes on cash, cash equivalents and restricted cash
-	-	-	-	-	-	-	-	-	-	0	-6	-9	-12	-8	-8	-6	-3	135	29	22	-2	-149	-42	-45	-28	-24	-18	-16	-6	-8	-19	-16	-17	0	0	0
Net decrease in cash, cash equivalents and restricted cash
-	-	-	-	-	-	-	-	-	-	-6,831	-697	-396	-4,960	-8,112	-18,999	-7,986	-7,777	-7,592	17,176	9,651	12,348	16,614	-6,377	-16,906	-6,874	-8,533	-224	10,908	-6,705	13	-7,646	-10,443	8,751	0	0	0
Supplemental Disclosure of Non-cash Information:
Purchase of property and equipment included in accounts payable and accrued expenses
0	-	-	-	0	-	-	-	0	-	-	-	0	-	-	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Offering costs remaining in accrued expenses
0	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-